Loading...
XSHE
300896
Market cap7.36bUSD
Jun 20, Last price  
171.47CNY
1D
1.04%
1Q
-9.80%
IPO
-9.80%
Name

Imeik Technology Development Co Ltd

Chart & Performance

D1W1MN
P/E
26.40
P/S
17.08
EPS
6.49
Div Yield, %
1.86%
Shrs. gr., 5y
6.84%
Rev. gr., 5y
40.24%
Revenues
3.03b
+5.45%
75,124,088111,817,498140,732,063222,489,964321,011,015557,715,652709,290,1971,447,872,0011,938,838,3632,869,347,2313,025,668,449
Net income
1.96b
+5.33%
28,419,40417,652,01053,377,01582,193,507122,854,839305,519,840439,748,783957,979,5851,263,558,4151,858,475,3021,957,596,837
CFO
1.93b
-2.76%
27,949,80048,345,80054,997,80084,158,823135,496,573309,715,080425,677,596942,779,5081,193,935,2031,981,901,4091,927,174,523
Dividend
Apr 29, 20243.2522 CNY/sh

Profile

Imeik Technology Development Co.,Ltd focuses on the research and development, production, and sale of biomedical materials. The company offers medical beauty field products, including Moisten Angel, IFRESH, Yimei, Hearty, Bonita Bonita, and Tightly. It also offers skin care products, including moisturizing lotions, anti-wrinkle firming kinetic energy liquids, essence creams, hydrating firming masks, chitosan B5 repair sprays, and purifying and brightening kinetic liquids. The company was founded in 2004 and is based in Beijing, China.
URL
https://www.imeik.net/
IPO date
Sep 28, 2020
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,025,668
5.45%
2,869,347
47.99%
1,938,838
33.91%
Cost of revenue
583,983
531,608
508,096
Unusual Expense (Income)
NOPBT
2,441,686
2,337,739
1,430,742
NOPBT Margin
80.70%
81.47%
73.79%
Operating Taxes
324,699
300,636
220,723
Tax Rate
13.30%
12.86%
15.43%
NOPAT
2,116,986
2,037,104
1,210,019
Net income
1,957,597
5.33%
1,858,475
47.08%
1,263,558
31.90%
Dividends
(1,004,754)
(454,356)
Dividend yield
1.13%
0.37%
Proceeds from repurchase of equity
(40,152)
BB yield
0.05%
Debt
Debt current
11,299
Long-term debt
52,030
74,920
96,779
Deferred revenue
2,350
4,148
Other long-term liabilities
3,372
2
Net debt
(3,742,391)
(5,721,966)
(4,439,691)
Cash flow
Cash from operating activities
1,927,175
1,981,901
1,193,935
CAPEX
(63,681)
Cash from investing activities
(1,265,959)
Cash from financing activities
(1,420,847)
(374,179)
FCF
1,609,151
2,034,746
1,064,777
Balance
Cash
4,392,528
3,937,226
3,843,273
Long term investments
(598,108)
1,859,660
704,497
Excess cash
3,643,137
5,653,418
4,450,827
Stockholders' equity
4,831,145
3,474,065
2,535,023
Invested Capital
4,335,345
3,051,807
3,457,065
ROIC
57.32%
62.59%
35.17%
ROCE
30.53%
35.67%
23.73%
EV
Common stock shares outstanding
301,169
302,542
216,360
Price
182.50
-37.99%
294.33
-48.03%
566.35
5.64%
Market cap
54,963,296
-38.28%
89,047,333
-27.33%
122,535,486
5.64%
EV
51,373,962
83,462,463
118,195,449
EBITDA
2,486,849
2,382,228
1,457,170
EV/EBITDA
20.66
35.04
81.11
Interest
2,550
2,384
3,148
Interest/NOPBT
0.10%
0.10%
0.22%